Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector

Immunologic Research

Volumn 36, Issue 1-3, 2006, Pages 101-117

  He, Yukai ^a   Falo Jr , Louis D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cell subsets; Genetic immunization; Lentivector; Skin DC network; T cell immunity

Indexed keywords

DNA VACCINE; LENTIVIRUS VECTOR; LUCIFERASE; PLASMID DNA; PLASMID VECTOR; RETROVIRUS VECTOR; VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ENCEPHALOMYELITIS; GENETIC IMMUNIZATION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 33947133309     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/ir:36:1:101     Document Type: Review

References (99)

1. Plotkin SA:Vaccines: past, present and future. Nat Med 2005;11: S5-11.
2. Plotkin SA: Six revolutions in vaccinology. Pediatr Infect Dis J 2005;24: 1-9.
3. Burton DR, Desrosiers RC, Doms RW, et al: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5: 233-236.
4. Seder RA, Hill AV: Vaccines against intracellular infections requiring cellular immunity. Nature 2000;406: 793-798.
5. Moore AC, Hill AV: Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004;199: 126-143.
6. Letvin NL: Progress toward an HIV vaccine. Annu Rev Med 2005;56: 213-223.
7. Robinson HL, Amara RR: T cell vaccines for microbial infections. Nat Med 2005;11: S25-32.
8. McMichael AJ: HIV vaccines. Annu Rev Immunol 2006;24: 227-255.
9. Autran B, Carcelain G, Combadiere B, Debre P: Therapeutic vaccines for chronic infections. Science 2004;305: 205-208.
10. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267: 1820-1825.
11. Learmont JC, Geczy AF, Mills J, et al: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999;340: 1715-1722.
12. Shiver JW, Emini EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004;55: 355-372.
13. Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A: Long-lived memory CD8(+) T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol 2006;36: 842-854.
14. Williams MA, Bevan MJ: Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J Immunol 2004;173: 6694-6702.
15. Jelley-Gibbs DM, Brown DM, Dibble JP, Haynes L, Eaton SM, Swain SL: Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J Exp Med 2005;202: 697-706.
16. Voltan R, Robert-Guroff M: Live recombinant vectors for AIDS vaccine development. Curr Mol Med 2003;3: 273-284.
17. Bennink JR,Yewdell JW, Smith GL, Moller C, Moss B: Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984;311: 578-579.
18. Kieny MP, Lathe R, Drillien R, et al: Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984;312: 163-166.
19. Moss B, Smith GL, Gerin JL, Purcell RH: Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984;311: 67-69.
20. Adamina M, Daetwiler S, Rosenthal R, Zajac P: Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opin Biol Ther 2005;5: 1211-1224.
21. Rayner JO, Dryga SA, Kamrud KI: Alphavirus vectors and vaccination. Rev Med Virol 2002;12: 279-296.
22. Barouch DH, Nabel GJ: Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005;16: 149-156.
23. Tatsis N, Ertl HC: Adenoviruses as vaccine vectors. Mol Ther 2004;10: 616-629.
24. Boyer JL, Kobinger G, Wilson JM, Crystal RG: Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 2005;16: 157-168.
25. Casimiro DR, Chen L, Fu TM, et al: Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77: 6305-6313.
26. Shiver JW, Fu TM, Chen L, et al: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415: 331-335.
27. Rosenberg SA, Zhai Y, Yang JC, et al: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90: 1894-1900.
28. Farina SF, Gao GP, Xiang ZQ, et al: Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001;75: 11603-11613.
29. Hofmann C, Loser P, Cichon G, Arnold W, Both GW, Strauss M: Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999;73: 6930-6936.
30. Esslinger C, Chapatte L, Finke D, et al: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003;111: 1673-1681.
31. Esslinger C, Romero P, MacDonald HR: Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 2002;13: 1091-1100.
32. He Y, Zhang J, Mi Z, Robbins P, Falo LD, Jr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005;174: 3808-3817.
33. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004;172: 1582-1587.
34. Hacein-Bey-Abin S, von Kalle C, Schmidt M, et al: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348: 255-256.
35. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302: 415-419.
36. Lu R, Nakajima N, Hofmann W, et al: Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol 2004;78: 658-668.
37. Saenz DT, Loewen N, Peretz M, et al: Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004;78: 2906-2920.
38. Vargas J, Jr, Gusella GL, Najfeld V, Klotman ME, Cara A: Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004;15: 361-372.
39. Yanez-Munoz RJ, Balaggan KS, Macneil A, et al: Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12: 348-353.
40. Collins MK, Cerundolo V: Gene therapy meets vaccine development. Trends Biotechnol 2004;22: 623-626.
41. Lever AM, Strappe PM, Zhao J: Lentiviral vectors. J Biomed Sci 2004;11: 439-449.
42. Quinonez R, Sutton RE: Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002;21: 937-951.
43. Breckpot K, Dullaers M, Bonehill A, et al: Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003;5: 654-667.
44. Dullaers M, Meirvenne SV, Heirman C, et al: Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006;13: 630-640.
45. Rowe HM, Lopes L, Ikeda Y, et al: Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 2006;13:310-319.
46. Esslinger C, Chapatte L, Finke D, et al: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003;111: 1673-1681.
47. Debrick JE, Campbell PA, Staerz UD: Macrophages as accessory cells for class I MHC-restricted immune responses. J Immunol 1991;147: 2846-2851.
48. Ciavarra RP, Buhrer K, Van Rooijen N, Tedeschi B: T cell priming against vesicular stomatitis virus analyzed in situ: red pulp macrophages, but neither marginal metallophilic nor marginal zone macrophages, are required for priming CD4+ and CD8+ T cells. J Immunol 1997;158: 1749-1755.
49. Sigal LJ, Crotty S, Andino R, Rock KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398: 77-80.
50. Jung S, Unutmaz D, Wong P, et al: In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17: 211-220.
51. Belz GT, Wilson NS, Smith CM, Mount AM, Carbone FR, Heath WR: Bone marrow-derived cells expand memory CD8(+) T cells in response to viral infections of the lung and skin. Eur J Immunol 2006.
52. Zammit DJ, Cauley LS, Pham QM, Lefrancois L: Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005;22: 561-570.
53. Belz GT, Smith CM, Kleinert L, et al: Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci USA 2004;101: 8670-8675.
54. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2: 151-161.
55. Villadangos JA, Heath WR: Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Sem Immunol 2005;17: 262-272.
56. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392: 245-252. 57. Larrengina AT, Falo LD: Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol 2005;124: 1-12.
57. Allan RS, Smith CM, Belz GT, et al: Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003;301: 1925-1928.
58. Belz GT, Smith CM, Eichner D, et al: Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004;172: 1996-2000.
59. Smith CM, Belz GT, Wilson NS, et al: Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003;170:4437-4440.
60. Belz GT, Shortman K, Bevan MJ, Heath WR: CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J Immunol 2005;175: 196-200.
61. Serbina NV, Pamer EG: Immunology. Giving credit where credit is due. Science 2003;301: 1856-1857.
62. Carbone FR, Belz GT, Heath WR: Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 2004;25: 655-658.
63. Heath WR, Belz GT, Behrens GM, et al: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199: 9-26.
64. Sevilla N, Kunz S, McGavern D, Oldstone MB: Infection of dendritic cells by lymphocytic choriomeningitis virus. Curr Top Microbiol Immunol 2003;276: 125-144.
65. Bosnjak L, Miranda-Saksena M, Koelle DM, Boadle RA, Jones CA, Cunningham AL: Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J Immunol 2005;174: 2220-2227.
66. Engelmayer J, Larsson M, Subklewe M, et al: Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999;163: 6762-6768.
67. Larsson M, Beignon AS, Bhardwaj N: DC-virus interplay: a double edged sword. Sem Immunol 2004;16: 147-161.
68. Larsson M, Fonteneau JF, Somersan S, et al: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001;31: 3432-3442.
69. Yewdell JW, Haeryfar SM: Understanding presentation of viral antigens to CD8(+) T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005;23: 651-682.
70. Iyoda T, Shimoyama S, Liu K, et al: The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195: 1289-1302.
71. VandenDriessche T, Thorrez L, Naldini L, et al: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002;100: 813-822.
72. Heath WR,Villadangos JA: No driving without a license. Nat Immunol 2005;6: 125-126.
73. Itano AA, McSorley SJ, Reinhardt RL, et al: Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003;19: 47-57.
74. Sporri R, Reis e Sousa C: Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005;6: 163-170.
75. Belshe RB, Newman FK, Cannon J, et al: Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351: 2286-2294.
76. Kenney RT, Frech SA, Muenz LR,Villar CP, Glenn GM: Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351: 2295-2301.
77. La Montagne JR, Fauci AS: Intradermal influenza vaccination - can less be more? N Engl J Med 2004;351: 2330-2332.
78. Kaech SM, Ahmed R: Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2: 415-422.
79. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG: Early programming of T cell populations responding to bacterial infection. J Immunol 2000;165: 6833-6839.
80. van Stipdonk MJ, Lemmens EE, Schoenberger SP: Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2: 423-429.
81. Wong P, Pamer EG: Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol 2001;166: 5864-5868.
82. Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F: Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci USA 2002;99: 11819-11824.
83. Wong P, Pamer EG: Feedback regulation of pathogen-specific T cell priming. Immunity 2003;18: 499-511.
84. Stock AT,Mueller SN, van Lint AL, Heath WR, Carbone FR: Cutting edge: prolonged antigen presentation after herpes simplex virus-1 skin infection. J Immunol 2004;173: 2241-2244.
85. Curtsinger JM, Johnson CM, Mescher MF: CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 2003; 171: 5165-5171.
86. van Stipdonk MJ, Hardenberg G, Bijker MS, et al: Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 2003;4: 361-365.
87. Curtsinger JM, Lins DC, Mescher MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197: 1141-1151.
88. Gett AV, Sallusto F, Lanzavecchia A, Geginat J: T cell fitness determined by signal strength. Nat Immunol 2003;4: 355-360.
89. Kim TW, Hung CF, Ling M, et al: Enhancing DNA vaccine potency by coadministration of DNA encoding anti-apoptotic proteins. J Clin Invest 2003;112: 109-117.
90. Obst R, van Santen HM,Mathis D, Benoist C: Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J Exp Med 2005;201: 1555-1565.
91. Yang TC, Millar J, Groves T, et al: The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006;176: 200-210.
92. Ritter U, Meissner A, Scheidig C, Korner H: CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. Eur J Immunol 2004;34: 1542-1550.
93. Zhao X, Deak E, Soderberg K, et al:Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003;197: 153-162.
94. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ: Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005;23: 611-620.
95. Bennett CL, van Rijn E, Jung S, et al: Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005;169: 569-576.
96. Kissenpfennig A, Henri S, Dubois B, et al: Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005;22: 643-654.
97. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG: Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002;8: 415-419.
98. Ramirez MC, Sigal LJ: Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells. J Immunol 2002;169: 6733-6742.
99. He Y, Zhang J, Donahue C, Falo LD, Jr.: Skin-derived dendritic cells induce potent CD8+ T cell immunity in recombinant lentivector-medicated genetic immunization. Immunity 2006;24: 643-656.